Population Pharmacokinetics of Magnesium Sulfate in Preeclampsia and Associated Factors

Abstract Background and Objective The pharmacokinetic basis of magnesium sulphate (MgSO4) dosing regimens for preeclampsia (PE) prophylaxis and treatment is not clearly established. The aim of study is to develop a population pharmacokinetic (PK) model of MgSO4 in PE, and to determine key covariates...

Full description

Bibliographic Details
Main Authors: Tatiana Xavier da Costa, Francine Johansson Azeredo, Marcela Abbott Galvão Ururahy, Miguel Adelino da Silva Filho, Rand Randall Martins, Antonio Gouveia Oliveira
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-07-01
Series:Drugs in R&D
Online Access:https://doi.org/10.1007/s40268-020-00315-2
id doaj-3073bbf12e94404faea53ba3c82e3d07
record_format Article
spelling doaj-3073bbf12e94404faea53ba3c82e3d072021-07-11T11:33:06ZengAdis, Springer HealthcareDrugs in R&D1174-58861179-69012020-07-0120325726610.1007/s40268-020-00315-2Population Pharmacokinetics of Magnesium Sulfate in Preeclampsia and Associated FactorsTatiana Xavier da Costa0Francine Johansson Azeredo1Marcela Abbott Galvão Ururahy2Miguel Adelino da Silva Filho3Rand Randall Martins4Antonio Gouveia Oliveira5Postgraduate Program in Pharmaceutical Sciences, Health Science Center, Federal University of Rio Grande do NortePost Graduate Program in Pharmacy, Faculty of Pharmacy, Federal University of BahiaDepartment of Clinical Analysis, Health Science Center, Federal University of Rio Grande do NorteHealth Department, Uninassau UniversityDepartment of Pharmacy, Health Science Center, Federal University of Rio Grande do NorteDepartment of Pharmacy, Health Science Center, Federal University of Rio Grande do NorteAbstract Background and Objective The pharmacokinetic basis of magnesium sulphate (MgSO4) dosing regimens for preeclampsia (PE) prophylaxis and treatment is not clearly established. The aim of study is to develop a population pharmacokinetic (PK) model of MgSO4 in PE, and to determine key covariates having an effect in MgSO4 pharmacokinetics in preeclampsia (PE) and to determine key covariates having an effect in MgSO4 PK. Methods A prospective cohort study was conducted from June 2016 to February 2018 in patients with PE administered MgSO4 as a 4-g bolus followed by continuous infusion at a rate of 1 g/h. Serum magnesium concentrations were obtained before treatment administration and 2, 6, 12, and 18 h after the initial dose. The software Monolix was used to estimate population PK parameters of MgSO4 [clearance (CL), volume of distribution (V), half-life] and to develop a PK model with baseline patient demographic, clinical, and laboratory covariates. Results The study population consisted of 109 patients. The PK profile of MgSO4 was adequately described by a one-compartment PK model. The model estimate of the population CL was 1.38 L/h; for V, it was 13.3 L; and the baseline magnesium concentration was 0.77 mmol/L (1.87 mg/dL). The baseline body weight and serum creatinine statistically influenced MgSO4 CL and V, respectively. The model was parameterized as CL and V. Conclusion The PK of MgSO4 in pregnant women with PE is significantly affected by creatinine and body weight. Pregnant women with PE and higher body weight have a higher V and, consequently, a lower elimination rate of MgSO4. Pregnant women with PE and a higher serum creatinine value show lower CL and, therefore, lower MgSO4 elimination rate.https://doi.org/10.1007/s40268-020-00315-2
collection DOAJ
language English
format Article
sources DOAJ
author Tatiana Xavier da Costa
Francine Johansson Azeredo
Marcela Abbott Galvão Ururahy
Miguel Adelino da Silva Filho
Rand Randall Martins
Antonio Gouveia Oliveira
spellingShingle Tatiana Xavier da Costa
Francine Johansson Azeredo
Marcela Abbott Galvão Ururahy
Miguel Adelino da Silva Filho
Rand Randall Martins
Antonio Gouveia Oliveira
Population Pharmacokinetics of Magnesium Sulfate in Preeclampsia and Associated Factors
Drugs in R&D
author_facet Tatiana Xavier da Costa
Francine Johansson Azeredo
Marcela Abbott Galvão Ururahy
Miguel Adelino da Silva Filho
Rand Randall Martins
Antonio Gouveia Oliveira
author_sort Tatiana Xavier da Costa
title Population Pharmacokinetics of Magnesium Sulfate in Preeclampsia and Associated Factors
title_short Population Pharmacokinetics of Magnesium Sulfate in Preeclampsia and Associated Factors
title_full Population Pharmacokinetics of Magnesium Sulfate in Preeclampsia and Associated Factors
title_fullStr Population Pharmacokinetics of Magnesium Sulfate in Preeclampsia and Associated Factors
title_full_unstemmed Population Pharmacokinetics of Magnesium Sulfate in Preeclampsia and Associated Factors
title_sort population pharmacokinetics of magnesium sulfate in preeclampsia and associated factors
publisher Adis, Springer Healthcare
series Drugs in R&D
issn 1174-5886
1179-6901
publishDate 2020-07-01
description Abstract Background and Objective The pharmacokinetic basis of magnesium sulphate (MgSO4) dosing regimens for preeclampsia (PE) prophylaxis and treatment is not clearly established. The aim of study is to develop a population pharmacokinetic (PK) model of MgSO4 in PE, and to determine key covariates having an effect in MgSO4 pharmacokinetics in preeclampsia (PE) and to determine key covariates having an effect in MgSO4 PK. Methods A prospective cohort study was conducted from June 2016 to February 2018 in patients with PE administered MgSO4 as a 4-g bolus followed by continuous infusion at a rate of 1 g/h. Serum magnesium concentrations were obtained before treatment administration and 2, 6, 12, and 18 h after the initial dose. The software Monolix was used to estimate population PK parameters of MgSO4 [clearance (CL), volume of distribution (V), half-life] and to develop a PK model with baseline patient demographic, clinical, and laboratory covariates. Results The study population consisted of 109 patients. The PK profile of MgSO4 was adequately described by a one-compartment PK model. The model estimate of the population CL was 1.38 L/h; for V, it was 13.3 L; and the baseline magnesium concentration was 0.77 mmol/L (1.87 mg/dL). The baseline body weight and serum creatinine statistically influenced MgSO4 CL and V, respectively. The model was parameterized as CL and V. Conclusion The PK of MgSO4 in pregnant women with PE is significantly affected by creatinine and body weight. Pregnant women with PE and higher body weight have a higher V and, consequently, a lower elimination rate of MgSO4. Pregnant women with PE and a higher serum creatinine value show lower CL and, therefore, lower MgSO4 elimination rate.
url https://doi.org/10.1007/s40268-020-00315-2
work_keys_str_mv AT tatianaxavierdacosta populationpharmacokineticsofmagnesiumsulfateinpreeclampsiaandassociatedfactors
AT francinejohanssonazeredo populationpharmacokineticsofmagnesiumsulfateinpreeclampsiaandassociatedfactors
AT marcelaabbottgalvaoururahy populationpharmacokineticsofmagnesiumsulfateinpreeclampsiaandassociatedfactors
AT migueladelinodasilvafilho populationpharmacokineticsofmagnesiumsulfateinpreeclampsiaandassociatedfactors
AT randrandallmartins populationpharmacokineticsofmagnesiumsulfateinpreeclampsiaandassociatedfactors
AT antoniogouveiaoliveira populationpharmacokineticsofmagnesiumsulfateinpreeclampsiaandassociatedfactors
_version_ 1721308879635087360